HRP20110458T1 - Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste - Google Patents
Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste Download PDFInfo
- Publication number
- HRP20110458T1 HRP20110458T1 HR20110458T HRP20110458T HRP20110458T1 HR P20110458 T1 HRP20110458 T1 HR P20110458T1 HR 20110458 T HR20110458 T HR 20110458T HR P20110458 T HRP20110458 T HR P20110458T HR P20110458 T1 HRP20110458 T1 HR P20110458T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- methyl
- triazolo
- cyclopentyl
- pyran
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 4
- 239000003112 inhibitor Substances 0.000 title claims 3
- 241000711549 Hepacivirus C Species 0.000 title claims 2
- 108060004795 Methyltransferase Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 -OR6 Chemical group 0.000 claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 26
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 239000012453 solvate Substances 0.000 claims abstract 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract 7
- 150000002367 halogens Chemical class 0.000 claims abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims abstract 2
- XTCSVDSGUHHIRY-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(5-ethylpyridin-3-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound CCC1=CN=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 XTCSVDSGUHHIRY-UHFFFAOYSA-N 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 24
- SLVAPEZTBDBAPI-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 SLVAPEZTBDBAPI-UHFFFAOYSA-N 0.000 claims 11
- HHXVQUXEUPSTEC-UHFFFAOYSA-N 2-[2-[2,6-bis(2,2,2-trifluoroethyl)pyridin-4-yl]ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(CC(F)(F)F)=NC(CC(F)(F)F)=C1 HHXVQUXEUPSTEC-UHFFFAOYSA-N 0.000 claims 7
- SHNZPCPBLPOEEZ-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(5-ethoxy-2-ethylpyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCOC1=CN=C(CC)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(C)C=NC3=N2)=C(O)C1 SHNZPCPBLPOEEZ-UHFFFAOYSA-N 0.000 claims 7
- CDOUPZXWEKOMRI-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(5-ethoxy-2-ethylpyridin-4-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound CCOC1=CN=C(CC)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C1 CDOUPZXWEKOMRI-UHFFFAOYSA-N 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 1
- QSZNBUCBMYJWFQ-UHFFFAOYSA-N 1-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-5-ethylpyridin-2-one Chemical compound C1=C(CC)C=CC(=O)N1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C1 QSZNBUCBMYJWFQ-UHFFFAOYSA-N 0.000 claims 1
- OBJZLLQBRVVCFZ-UHFFFAOYSA-N 2-[2-(6-amino-5-ethyl-2-methylpyridin-3-yl)ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound N1=C(N)C(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1C OBJZLLQBRVVCFZ-UHFFFAOYSA-N 0.000 claims 1
- NYHBKPWOGSMOKS-UHFFFAOYSA-N 2-[2-[2,6-bis(2,2,2-trifluoroethyl)pyridin-4-yl]ethyl]-2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(CC(F)(F)F)=NC(CC(F)(F)F)=C1 NYHBKPWOGSMOKS-UHFFFAOYSA-N 0.000 claims 1
- WUGYLLGNMCSUQM-UHFFFAOYSA-N 2-[3-chloro-5-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]pyridin-2-yl]-2-methylpropanenitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CN=C(C(C)(C)C#N)C(Cl)=C1 WUGYLLGNMCSUQM-UHFFFAOYSA-N 0.000 claims 1
- IDEGWCVLXNUCSN-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C=C(C)C=NC4=N3)=C(O)C2)C2CCCC2)=C1 IDEGWCVLXNUCSN-UHFFFAOYSA-N 0.000 claims 1
- XSJDVMHGTQZGEX-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2,6-dimethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound CC1=NC(C)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 XSJDVMHGTQZGEX-UHFFFAOYSA-N 0.000 claims 1
- KPAFBURYLWOICR-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2-ethyl-5-methoxypyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound C1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C=C(C)C=NC4=N3)=C(O)C2)C2CCCC2)=C1OC KPAFBURYLWOICR-UHFFFAOYSA-N 0.000 claims 1
- OOMDKIXNOABGDK-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2-ethyl-5-propoxypyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCCOC1=CN=C(CC)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(C)C=NC3=N2)=C(O)C1 OOMDKIXNOABGDK-UHFFFAOYSA-N 0.000 claims 1
- MHCUPLMWUDBQRC-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(4-ethylpyridin-2-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCC1=CC=NC(CCC2(OC(=O)C(CC3=NN4C=C(C)C=NC4=N3)=C(O)C2)C2CCCC2)=C1 MHCUPLMWUDBQRC-UHFFFAOYSA-N 0.000 claims 1
- AMRCSUYOSNECRQ-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(2-ethylpyridin-4-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound C1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 AMRCSUYOSNECRQ-UHFFFAOYSA-N 0.000 claims 1
- JVHCCHFIDUHSFQ-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-2-[2-(5-methoxy-2-methylpyridin-4-yl)ethyl]-3h-pyran-6-one Chemical compound COC1=CN=C(C)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C1 JVHCCHFIDUHSFQ-UHFFFAOYSA-N 0.000 claims 1
- LSVVRTCYQRPZKJ-UHFFFAOYSA-N 5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-2-[2-(2-ethylpyridin-4-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound C1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C=C(Cl)C=NC4=N3)=C(O)C2)C2CCCC2)=C1 LSVVRTCYQRPZKJ-UHFFFAOYSA-N 0.000 claims 1
- BXJRDNRTFGJWJN-UHFFFAOYSA-N 5-bromo-1-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]pyridin-2-one Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCN1C=C(Br)C=CC1=O BXJRDNRTFGJWJN-UHFFFAOYSA-N 0.000 claims 1
- SFSXNVBMAODLGN-UHFFFAOYSA-N Ethyl-2 methyl-6 pyridine Natural products CCC1=CC=CC(C)=N1 SFSXNVBMAODLGN-UHFFFAOYSA-N 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Spoj formule (4), naznačen time što: R1 je ciklopentil; R2 je -(CR6R7)n(5-6-eročlani heterocikl), gdje je navedena 5-6-eročlana heterociklička skupina izborno supstituirana s najmanje jednom skupinom R4;R3 je -(CR6R7)t(4-10-eročlani heterocikl), izborno supstituiran s najmanje jednom skupinom R5;svakog R4 se neovisno bira između halogena, -OR6, okso, -NR6R7, -CF3, -CN, -C(O)R6, -C(O)OR6, -OC(O)R6, -NR6C(O)R7, -NR6C(O)OR7, -NR6C(O)NR6R7, -C(O)NR6R7, -SO2NR6R7, -NR6SO2R7, C1-C6 alkila, C2-C6 alkenila i C2-C6 alkinila, gdje su navedene C1-C6 alkilna, C2-C6 alkenilna i C2-C6 alkinilna skupina izborno supstituirane s najmanje jedan R5;svakog R5 se neovisno bira između C1-C6 alkila, halogena, -OR6, -CF3 i -CN; svakog R6 i R7 se neovisno bira između vodika i C1-C6 alkila; n je 2; it je 1 ili 2; ili njegova farmaceutski prihvatljiva sol ili solvat, uz uvjet da spoj formule (4) nije 6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-on, 3-[(6-klor[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-ciklopentil-6-[2-(2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-on ili 6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etilpiridin-3-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-on. Patent sadrži još 22 patentna zahtjeva.
Claims (23)
1. Spoj formule (4),
[image]
naznačen time što:
R1 je ciklopentil;
R2 je -(CR6R7)n(5-6-eročlani heterocikl), gdje je navedena 5-6-eročlana heterociklička skupina izborno supstituirana s najmanje jednom skupinom R4;
R3 je -(CR6R7)t(4-10-eročlani heterocikl), izborno supstituiran s najmanje jednom skupinom R5;
svakog R4 se neovisno bira između halogena, -OR6, okso, -NR6R7, -CF3, -CN, -C(O)R6, -C(O)OR6, -OC(O)R6, -NR6C(O)R7, -NR6C(O)OR7, -NR6C(O)NR6R7, -C(O)NR6R7, -SO2NR6R7, -NR6SO2R7, C1-C6 alkila, C2-C6 alkenila i C2-C6 alkinila, gdje su navedene C1-C6 alkilna, C2-C6 alkenilna i C2-C6 alkinilna skupina izborno supstituirane s najmanje jedan R5;
svakog R5 se neovisno bira između C1-C6 alkila, halogena, -OR6, -CF3 i -CN;
svakog R6 i R7 se neovisno bira između vodika i C1-C6 alkila;
n je 2; i
t je 1 ili 2;
ili njegova farmaceutski prihvatljiva sol ili solvat,
uz uvjet da spoj formule (4) nije 6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-on, 3-[(6-klor[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-ciklopentil-6-[2-(2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-on ili 6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etilpiridin-3-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-on.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što t je 1.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R2 je -(CH2)2(piridil), -(CH2)2(pirazolil), -(CH2)2(pirolil), -(CH2)2(oksazolil), -(CH2)2(tiazolil), -(CH2)2(imidazolil), -(CH2)2(izoksazolil), -(CH2)2(izotiazolil), -(CH2)2(1,2,3-triazolil), -(CH2)2(1,3,4-triazolil), -(CH2)2(1,3,4-tiadiazolil), -(CH2)2(piridazinil), -(CH2)2(pirimidinil), -(CH2)2(pirazinil) ili -(CH2)2(1,3,5-triazinil) skupina, od kojih je svaki izborno supstituiran s najmanje jednom skupinom R4.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što R3 je -(CH2)([1,2,4]triazolo[1,5-a]pirimidin-2-il), izborno supstituiran s najmanje jednom skupinom R5.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što R2 je -(CH2)2(piridil), -(CH2)2(pirazolil) ili -(CH2)2(pirolil), od kojih je svaki izborno supstituiran s najmanje jednom skupinom R4.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što R2 je -(CH2)2(piridil) ili -(CH2)2(pirazolil), od kojih je svaki izborno supstituiran s najmanje jednom skupinom R4.
7. Spoj u skladu s patentnim zahtjevom 6, naznačen time što:
R2 je -(CH2)2(piridil) ili -(CH2)2(pirazolil), od kojih je svaki izborno supstituiran s najmanje jednim supstituentom, kojeg se bira između halogena, C1-C6 alkila, -OR6 i -NR6R7; i
R3 je -(CH2)([1,2,4]triazolo[1,5-a]pirimidin-2-il), izborno supstituiran s najmanje jednim supstituentom, kojeg se bira između halogena i C1-C6 alkila.
8. Spoj u skladu s patentnim zahtjevom 7, naznačen time što R2 je -(CH2)2(piridil), izborno supstituiran s najmanje jednim supstituentom, kojeg se bira između halogena, C1-C6 alkila, -OR6 i -NR6R7.
9. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između:
6-[2-(6-amino-5-etil-2-metilpiridin-3-il)etil]-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(4-etilpiridin-2-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(4-etilpiridin-2-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(2,6-dimetilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-6-[2-(2-isopropilpiridin-4-il)etil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-6-isopropilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-6-metilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(6-etil-3-metoksipiridin-2-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(1-etil-1H-pirazol-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-6-[2-(1-isopropil-1H-pirazol-4-il)etil]-5,6-dihidro-2H-piran-2-ona;
6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-6-[2-(5-metoksi-2-metilpiridin-4-il)etil]-5,6-dihidro-2H-piran-2-ona;
6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
5-brom-1-(2-{2-ciklopentil-5-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-6-okso-3,6-dihidro-2H-piran-2-il}etil)piridin-2(1H)-ona;
1-(2-{2-ciklopentil-5-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-6-okso-3,6-dihidro-2H-piran-2-il}etil)-5-etilpiridin-2(1H)-ona;
2-[3-klor-5-(2-{2-ciklopentil-5-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-6-okso-3,6-dihidro-2H-piran-2-il}etil)piridin-2-il]-2-metilpropanenitrile;
(+)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona; i
(–)-6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
ili njihovih farmaceutski prihvatljivih soli ili solvata.
10. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između:
(+)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona; i
(–)-6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
ili njihovih farmaceutski prihvatljivih soli ili solvata.
11. Spoj u skladu s patentnim zahtjevom 10, naznačen time što ga se bira između:
(+)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(+)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona; i
(+)-6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
ili njihovih farmaceutski prihvatljivih soli ili solvata.
12. Spoj u skladu s patentnim zahtjevom 10, naznačen time što ga se bira između:
(–)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-metoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
(–)-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(2-etil-5-propoksipiridin-4-il)etil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona; i
(–)-6-ciklopentil-6-[2-(5-etoksi-2-etilpiridin-4-il)etil]-4-hidroksi-3-[(6-metil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-5,6-dihidro-2H-piran-2-ona;
ili njihovih farmaceutski prihvatljivih soli ili solvata.
13. Spoj u skladu s patentnim zahtjevom 10, naznačen time što je (+)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-on; ili njegova farmaceutski prihvatljiva sol ili solvat.
14. Spoj u skladu s patentnim zahtjevom 10, naznačen time što je (–)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-on; ili njegova farmaceutski prihvatljiva sol ili solvat.
15. Spoj u skladu s patentnim zahtjevom 10, naznačen time što je (+)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-on; ili njegova farmaceutski prihvatljiva sol ili solvat.
16. Spoj u skladu s patentnim zahtjevom 10, naznačen time što je (–)-6-{2-[2,6-bis(2,2,2-trifluoretil)piridin-4-il]etil}-6-ciklopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-on; ili njegova farmaceutski prihvatljiva sol ili solvat.
17. Farmaceutski pripravak, naznačen time što sadrži terapijski djelotvornu količinu spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegove farmaceutski prihvatljive sol ili solvata, i farmaceutski prihvatljivu podlogu.
18. Kombinacija, naznačena time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegovu farmaceutski prihvatljivu sol ili solvat, i jedan ili više inhibitora HCV.
19. Kombinacija u skladu s patentnim zahtjevom 18, naznačena time što spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16 se bira između:
(+)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona; i
(–)-6-ciklopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-4-hidroksi-5,6-dihidro-2H-piran-2-ona;
ili njihovih farmaceutski prihvatljivih soli ili solvata.
20. Proizvod, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegovu farmaceutski prihvatljivu sol ili solvat, i jedan ili više inhibitora HCV, kao kombinirani pripravak za istodobnu, uzastopnu ili odvojenu upotrebu u liječenju infekcije virusom hepatitisa C.
21. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol ili solvat, naznačena time što je namijenjen upotrebi kao medikament.
22. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegove farmaceutski prihvatljive soli ili solvata, ili farmaceutskog pripravka u skladu s patentnim zahtjevom 17, ili kombinacije u skladu s bilo kojim od patentnih zahtjeva 18 do 19, naznačena time što su navedeni spoj, pripravak ili kombinacija namiijenjeni pripravi medikamenta za liječenje sisavca koji boluje od infekcije virusom hepatitisa C.
23. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol ili solvat; naznačen time što je namijenjen upotrebi u liječenju infekcije virusom hepatitisa C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60261804P | 2004-08-18 | 2004-08-18 | |
PCT/IB2005/002697 WO2006018725A1 (en) | 2004-08-18 | 2005-08-05 | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110458T1 true HRP20110458T1 (hr) | 2011-07-31 |
Family
ID=35429645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110458T HRP20110458T1 (hr) | 2004-08-18 | 2011-06-17 | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste |
Country Status (43)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS51794B (en) * | 2004-08-18 | 2011-12-31 | Pfizer Inc. | RNA SUBSTITUTE RNA POLYMERASE INHIBITORS OF HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS USING THEM |
KR101064459B1 (ko) * | 2005-08-24 | 2011-09-16 | 화이자 인코포레이티드 | Hcv 폴리머라제 억제제의 제조 방법 |
US8258116B2 (en) | 2007-05-04 | 2012-09-04 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
EP2008996A1 (en) * | 2007-06-27 | 2008-12-31 | Syngeta Participations AG | Process for the production of pyrazoles |
EP2280989B1 (en) | 2008-06-06 | 2016-02-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
EP2320905B1 (en) | 2008-08-11 | 2017-06-28 | Glaxosmithkline LLC | Novel adenine derivatives |
EA201100114A1 (ru) | 2008-08-11 | 2011-10-31 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
UY32940A (es) | 2009-10-27 | 2011-05-31 | Bayer Cropscience Ag | Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas |
CN102596201A (zh) | 2009-10-30 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案 |
EP2325173A1 (de) | 2009-11-19 | 2011-05-25 | Bayer CropScience AG | Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden |
EA201200890A1 (ru) * | 2009-12-18 | 2013-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Комбинированная терапия hcv |
KR101773541B1 (ko) | 2010-02-10 | 2017-08-31 | 글락소스미스클라인 엘엘씨 | 6-아미노-2-{[(1s)-1-메틸부틸]옥시}-9-[5-(1-피페리디닐)-7,9-디하이드로-8h-퓨린-8-온 말레이트 |
EP2534148A1 (en) | 2010-02-10 | 2012-12-19 | GlaxoSmithKline LLC | Purine derivatives and their pharmaceutical uses |
DK2571854T3 (en) | 2010-05-20 | 2015-02-09 | Bayer Ip Gmbh | PROCESS FOR THE PREPARATION OF 1-alkyl-3-difluoromethyl-5-hydroxypyrazoles |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
FR2972452B1 (fr) * | 2011-03-09 | 2013-03-15 | Rhodia Operations | Procede de preparation du difluoroacetonitrile et de ses derives |
MX348274B (es) | 2012-05-14 | 2017-06-02 | Bayer Cropscience Ag | Procedimiento de preparacion de cloruros de 1-alquil-3-fluoroalqui l-1h-pirazol-4-carbonilo. |
EP2922548A4 (en) | 2012-11-21 | 2016-06-01 | Stategics Inc | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROPOLATION, DIFFERENTIATION AND OVER LIVING |
ES2610380T3 (es) | 2013-01-17 | 2017-04-27 | Bayer Cropscience Ag | Procedimiento de preparación de 5-fluoro-1-metil-3-difluorometil-1H-pirazol-4-carbaldehído |
JP6321042B2 (ja) | 2013-02-06 | 2018-05-09 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 新規なハロゲン置換された化合物 |
ES2683693T3 (es) | 2014-01-03 | 2018-09-27 | Bayer Animal Health Gmbh | Nuevas pirazolil-heteroarilamidas como agentes plaguicidas |
KR102319577B1 (ko) | 2014-01-24 | 2021-10-29 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 1-알킬-3-디플루오로메틸-5-플루오르-1h-피라졸-4-카르브알데히드 및 1-알킬-3-디플루오로메틸-5-플루오르-1h-피라졸-4-카르복실레이트의 제조 방법 |
RU2676684C2 (ru) | 2014-02-20 | 2019-01-10 | ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА |
MX2016015923A (es) | 2014-06-03 | 2017-02-27 | Actelion Pharmaceuticals Ltd | Compuestos de pirazol y su uso como bloqueadores de canales de calcio tipo t. |
US10584125B2 (en) | 2014-11-13 | 2020-03-10 | Glaxosmithkline Biologicals Sa | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
WO2017093180A1 (de) | 2015-12-01 | 2017-06-08 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
KR101949108B1 (ko) | 2015-12-03 | 2019-02-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드 |
SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
US10660334B2 (en) | 2016-08-15 | 2020-05-26 | Bayer Cropscience Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
DK3554490T3 (da) | 2016-12-16 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | Farmaceutisk kombination omfattende en calciumkanalblokker type T |
MX2019009242A (es) | 2017-02-06 | 2019-09-13 | Idorsia Pharmaceuticals Ltd | Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-c iclopropanos. |
KR102622644B1 (ko) | 2017-10-04 | 2024-01-10 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로시클릭 화합물의 유도체 |
WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
BR112020017624A2 (pt) | 2018-03-12 | 2020-12-22 | Bayer Aktiengesellschaft | Derivados heterocíclicos bicíclicos condensados como agentes de controle de pragas |
MX2020011061A (es) | 2018-04-20 | 2020-11-06 | Bayer Ag | Derivados de heterocicleno como agentes para el control de plagas. |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
WO2020232375A1 (en) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
WO2020232378A1 (en) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
CN112194620B (zh) * | 2020-12-04 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种2-乙基-4-氰基吡啶的制备方法 |
CN113563167B (zh) * | 2021-07-16 | 2023-09-08 | 南通华祥医药科技有限公司 | 一种2-甲基-1-四氢萘酮的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3786063A (en) * | 1971-05-24 | 1974-01-15 | Universal Oil Prod Co | Thiazolethiosulfonates |
DE2155360C3 (de) * | 1971-11-08 | 1980-04-03 | Cassella Ag, 6000 Frankfurt | Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern |
CA1140049A (en) * | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
US4326058A (en) * | 1979-02-05 | 1982-04-20 | Sumitomo Chemical Company, Limited | Organo-phosphoric esters and their production and use |
US4489077A (en) * | 1983-03-23 | 1984-12-18 | Warner-Lambert Company | 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides |
US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
AU688344B2 (en) * | 1993-07-19 | 1998-03-12 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Hepatitis C virus proliferation inhibitor |
US5789440A (en) * | 1993-11-19 | 1998-08-04 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
US5504104A (en) * | 1993-11-19 | 1996-04-02 | Warner-Lambert Company | Tricyclic pyrone derivatives as protease inhibitors and antiviral agents |
EP0729463B1 (en) | 1993-11-19 | 2002-05-22 | PARKE DAVIS & COMPANY | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
HUT77668A (hu) | 1993-11-19 | 1998-07-28 | Parke, Davis & Company | Vírusellenes hatású 5,6-dihidropiron-származékok és hatóanyagként azokat tartalmazó gyógyszerkészítmények |
US6005103A (en) * | 1993-11-19 | 1999-12-21 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
US5834506A (en) | 1996-11-01 | 1998-11-10 | Warner-Lambert Company | Dihydropyrones with improved antiviral activity |
NZ510013A (en) * | 1998-09-11 | 2003-11-28 | Warner Lambert Co | Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors |
US6512006B1 (en) * | 1999-12-09 | 2003-01-28 | Warner-Lambert Company | HIV protease inhibitors |
EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
DOP2003000641A (es) * | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
US7148226B2 (en) * | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
RS51794B (en) * | 2004-08-18 | 2011-12-31 | Pfizer Inc. | RNA SUBSTITUTE RNA POLYMERASE INHIBITORS OF HEPATITIS C VIRUS AND COMPOSITIONS AND TREATMENTS USING THEM |
-
2005
- 2005-08-05 RS RS20110257A patent/RS51794B/en unknown
- 2005-08-05 KR KR1020077006118A patent/KR100851178B1/ko active IP Right Grant
- 2005-08-05 SI SI200531314T patent/SI1781662T1/sl unknown
- 2005-08-05 MX MX2007001527A patent/MX2007001527A/es active IP Right Grant
- 2005-08-05 JP JP2007526609A patent/JP4372195B2/ja active Active
- 2005-08-05 PT PT05775853T patent/PT1781662E/pt unknown
- 2005-08-05 CA CA2577525A patent/CA2577525C/en not_active Expired - Fee Related
- 2005-08-05 WO PCT/IB2005/002697 patent/WO2006018725A1/en active Application Filing
- 2005-08-05 UA UAA200700852A patent/UA88909C2/ru unknown
- 2005-08-05 ES ES05775853T patent/ES2361845T3/es active Active
- 2005-08-05 EA EA200700338A patent/EA012605B1/ru not_active IP Right Cessation
- 2005-08-05 NZ NZ552874A patent/NZ552874A/en not_active IP Right Cessation
- 2005-08-05 GE GEAP200510998A patent/GEP20115305B/en unknown
- 2005-08-05 DK DK05775853.4T patent/DK1781662T3/da active
- 2005-08-05 GE GEAP20059868A patent/GEP20094751B/en unknown
- 2005-08-05 AP AP2007003918A patent/AP2313A/xx active
- 2005-08-05 CN CN2009101381353A patent/CN101538268B/zh active Active
- 2005-08-05 PL PL05775853T patent/PL1781662T3/pl unknown
- 2005-08-05 CN CN2005800280919A patent/CN101006092B/zh active Active
- 2005-08-05 AU AU2005273619A patent/AU2005273619B2/en not_active Ceased
- 2005-08-05 AT AT05775853T patent/ATE506364T1/de active
- 2005-08-05 DE DE602005027580T patent/DE602005027580D1/de active Active
- 2005-08-05 BR BRPI0514425-6A patent/BRPI0514425A/pt not_active IP Right Cessation
- 2005-08-05 EP EP05775853A patent/EP1781662B1/en active Active
- 2005-08-12 MY MYPI20053809A patent/MY146123A/en unknown
- 2005-08-15 UY UY29068A patent/UY29068A1/es not_active Application Discontinuation
- 2005-08-15 US US11/204,269 patent/US7151105B2/en not_active Expired - Fee Related
- 2005-08-15 PE PE2005000945A patent/PE20060677A1/es not_active Application Discontinuation
- 2005-08-16 AR ARP050103438A patent/AR050699A1/es active IP Right Grant
- 2005-08-16 GT GT200500221A patent/GT200500221A/es unknown
- 2005-08-17 TW TW094128016A patent/TWI376379B/zh active
- 2005-08-17 NL NL1029755A patent/NL1029755C2/nl not_active IP Right Cessation
- 2005-08-18 SV SV2005002202A patent/SV2007002202A/es not_active Application Discontinuation
- 2005-08-18 HN HN2005000449A patent/HN2005000449A/es unknown
-
2006
- 2006-09-06 US US11/470,540 patent/US7622605B2/en not_active Expired - Fee Related
-
2007
- 2007-01-24 IL IL180933A patent/IL180933A/en not_active IP Right Cessation
- 2007-01-26 ZA ZA200700779A patent/ZA200700779B/xx unknown
- 2007-02-15 NI NI200700043A patent/NI200700043A/es unknown
- 2007-02-16 MA MA29684A patent/MA28803B1/fr unknown
- 2007-02-16 CR CR8935A patent/CR8935A/es unknown
- 2007-02-16 TN TNP2007000066A patent/TNSN07066A1/fr unknown
- 2007-02-16 EC EC2007007264A patent/ECSP077264A/es unknown
- 2007-03-08 NO NO20071274A patent/NO20071274L/no not_active Application Discontinuation
-
2008
- 2008-01-07 HK HK08100120.5A patent/HK1109617A1/xx not_active IP Right Cessation
- 2008-07-20 IL IL192919A patent/IL192919A0/en unknown
-
2009
- 2009-07-15 US US12/503,286 patent/US8268835B2/en not_active Expired - Fee Related
-
2011
- 2011-03-21 CR CR20110153A patent/CR20110153A/es unknown
- 2011-05-17 CY CY20111100486T patent/CY1111480T1/el unknown
- 2011-06-17 HR HR20110458T patent/HRP20110458T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110458T1 (hr) | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste | |
JP5911638B2 (ja) | ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用 | |
JP7335003B2 (ja) | Shp2ホスファターゼアロステリック阻害物質 | |
AU2016368317B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
RU2380101C2 (ru) | Бициклические пиримидины, ингибирующие hcv | |
KR101967172B1 (ko) | 인플루엔자 바이러스 복제의 억제제 | |
TW202122387A (zh) | Mta協同性之prmt5抑制劑 | |
KR20150000871A (ko) | 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도 | |
JP7159307B2 (ja) | Atrキナーゼの複素環式阻害剤 | |
WO2016046530A1 (en) | Novel compounds | |
JP2020527588A5 (hr) | ||
AU2017376541B2 (en) | Inhibitors of influenza virus replication and uses thereof | |
CA2429728A1 (en) | Tyrosine kinase inhibitors | |
JP2012501312A5 (hr) | ||
KR20120089648A (ko) | 결핵 억제제로서의 피리미딘 화합물 | |
JP2012528166A5 (hr) | ||
RU2007130896A (ru) | Индольные производные для лечения вирусных инфекций | |
KR20140024203A (ko) | 피리돈 및 아자-피리돈 화합물 및 사용 방법 | |
JP2009513571A (ja) | ヤヌスキナーゼ阻害剤として有用なデアザプリン | |
KR102440843B1 (ko) | Hiv 역전사효소 억제제의 전구약물 | |
CN101918079A (zh) | 蛋白激酶抑制剂及其用途 | |
JP2020527593A5 (hr) | ||
RU2018124788A (ru) | Замещенные бензазиноны в качестве антибактериальных соединений | |
JP2011524359A (ja) | 3環式インドール誘導体およびその使用方法 | |
CA3213088A1 (en) | Substituted 1-aryl-1'-heteroaryl compounds, substituted 1,1'-biheteroaryl compounds, and methods using same |